JP2002529707A - 癌関連抗原およびそれらの同定の方法 - Google Patents

癌関連抗原およびそれらの同定の方法

Info

Publication number
JP2002529707A
JP2002529707A JP2000580006A JP2000580006A JP2002529707A JP 2002529707 A JP2002529707 A JP 2002529707A JP 2000580006 A JP2000580006 A JP 2000580006A JP 2000580006 A JP2000580006 A JP 2000580006A JP 2002529707 A JP2002529707 A JP 2002529707A
Authority
JP
Japan
Prior art keywords
tumor
antibody
associated antigen
vaccine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000580006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002529707A5 (enExample
Inventor
デイル アンドー，
ジュ−フェイ チャン，
ジェームス マッカーサー，
マーゴ ロバーツ，
ジョナソン シモンズ，
Original Assignee
セル ジェネシス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル ジェネシス インコーポレイテッド filed Critical セル ジェネシス インコーポレイテッド
Publication of JP2002529707A publication Critical patent/JP2002529707A/ja
Publication of JP2002529707A5 publication Critical patent/JP2002529707A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2000580006A 1998-11-03 1999-11-03 癌関連抗原およびそれらの同定の方法 Pending JP2002529707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10679598P 1998-11-03 1998-11-03
US60/106,795 1998-11-03
PCT/US1999/025936 WO2000026676A1 (en) 1998-11-03 1999-11-03 Cancer-associated antigens and methods of their identification

Publications (2)

Publication Number Publication Date
JP2002529707A true JP2002529707A (ja) 2002-09-10
JP2002529707A5 JP2002529707A5 (enExample) 2006-12-21

Family

ID=22313292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000580006A Pending JP2002529707A (ja) 1998-11-03 1999-11-03 癌関連抗原およびそれらの同定の方法

Country Status (7)

Country Link
US (2) US7226606B2 (enExample)
EP (1) EP1125133A1 (enExample)
JP (1) JP2002529707A (enExample)
KR (1) KR20010080384A (enExample)
AU (1) AU767842B2 (enExample)
CA (1) CA2349217C (enExample)
WO (1) WO2000026676A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531521A (ja) * 1998-12-10 2002-09-24 オニバックス リミティド ガンの新規処置
JP2006525995A (ja) * 2003-04-02 2006-11-16 セル ジェネシス インコーポレイテッド サイトカイン発現細胞ワクチンの組み合わせ
JP2011511772A (ja) * 2008-01-31 2011-04-14 アジルクス リミテッド ワクチン組成物
JP2017165734A (ja) * 2011-01-04 2017-09-21 シラジェン バイオセラピューティクス インコーポレイテッド 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
WO2008109030A2 (en) 2007-03-02 2008-09-12 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20080267935A1 (en) * 2007-04-06 2008-10-30 Cell Genesys, Inc. AraC in combination with a cytokine-secreting cell and methods of use thereof
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
CA2922835C (en) 2013-09-06 2023-09-26 New York University Method for inducing antitumor immunity using sindbis viral vectors and tumor associated antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6009056563, ＳＩＭＯＮＳ，Ｊ．Ｗ． ｅｔ ａｌ, "Ｂｉｏａｃｔｉｖｉｔｙ ｏｆ ａｕｔｏｌｏｇｏｕｓ ｉｒｒａｄｉａｔｅｄ ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ ｖａｃｃｉｎｅｓ ｇｅｎｅｒａｔｅｄ ｂｙ ｅｘ ｖｉｖｏ ＧＭ−ＣＳＦ ｇｅｎｅ ｔｒａｎｓ", Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ａｓｓｏｃｉａｔｉｏｎ ｆｏｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ａｎｎｕａｌ Ｍｅｅｔｉｎｇ, 1998, Ｖｏｌ．３９, ｐ．３６９−３７０ *
JPN6009056566, ＳＩＭＯＮＳ，Ｊ．Ｗ．, "Ｂｉｏａｃｔｉｖｉｔｙ ｏｆ ｈｕｍａｎ ＧＭ−ＣＳＦ ｇｅｎｅ ｔｈｅｒａｐｙ ｉｎ ｍｅｔａｓｔａｔｉｃ ｒｅｎａｌ ｃｅｌｌ ｃａｒｃｉｎｏｍａ ａｎｄ ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ", Ｈｉｎｙｏｋｉｋａ Ｋｉｙｏ, 1997, Ｖｏｌ．４３， Ｎｏ．１１, ｐ．８２１−２ *
JPN6009056568, ＣＡＲＤＵＣＣＩ，Ｍ．Ａ． ｅｔ ａｌ, "Ｐｒｏｓｔａｔｅ ｃａｎｃｅｒ ｔｒｅａｔｍｅｎｔ ｓｔｒａｔｅｇｉｅｓ ｂａｓｅｄ ｏｎ ｔｕｍｏｒ−ｓｐｅｃｉｆｉｃ ｂｉｏｌｏｇｉｃａｌ ｐｒｉｎｃｉｐｌｅｓ： ｆｕｔｕｒｅ ｄｉｒｅｃｔｉｏｎ", Ｓｅｍｉｎ Ｏｎｃｏｌ, 1996, Ｖｏｌ．２３， Ｎｏ．６ Ｓｕｐｐｌ １４, ｐ．５６−６２ *
JPN7010002221, ＬＡＲＲＡＮ，Ｊ． ｅｔ ａｌ, "Ｉｎ ｖｉｔｒｏ ｃｈａｒａｃｔｅｒｉｚａｔｉｏｎ ｏｆ ｂｏｍｂｅｓｉｎ ａｎｄ ｃａｌｃｉｔｏｎｉｎ ｏｎ ｔｈｅ ｐｒｏｌｉｆｅｒａｔｉｏｎ ｏｆ ＰＣ３， ＤＵ １４５ ａｎｄ ＬＮＣａＰ ｃ", Ｉｎｔ Ｊ Ｄｅｖ Ｂｉｏｌ, 1996, Ｖｏｌ．Ｓｕｐｐｌ １, ｐ．２７５Ｓ−２７６Ｓ *
JPN7010002222, ＯＫＡＭＯＴＯ，Ｍ． ｅｔ ａｌ, "Ｉｎｔｅｒｌｅｕｋｉｎ−６ ａｓ ａ ｐａｒａｃｒｉｎｅ ａｎｄ ａｕｔｏｃｒｉｎｅ ｇｒｏｗｔｈ ｆａｃｔｏｒ ｉｎ ｈｕｍａｎ ｐｒｏｓｔａｔｉｃ ｃａｒｃｉｎｏｍａ ｃｅｌｌｓ ｉｎ ｖｉｔｒｏ", Ｃａｎｃｅｒ Ｒｅｓ, 1997, Ｖｏｌ．５７， Ｎｏ．１, ｐ．１４１−６ *
JPN7010002223, ＲＯＫＨＬＩＮ，Ｏ．Ｗ． ｅｔ ａｌ, "Ｆａｓ−ｍｅｄｉａｔｅｄ ａｐｏｐｔｏｓｉｓ ｉｎ ｈｕｍａｎ ｐｒｏｓｔａｔｉｃ ｃａｒｃｉｎｏｍａ ｃｅｌｌ ｌｉｎｅｓ", Ｃａｎｃｅｒ Ｒｅｓ, 1997, Ｖｏｌ．５７， Ｎｏ．９, ｐ．１７５８−６８ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531521A (ja) * 1998-12-10 2002-09-24 オニバックス リミティド ガンの新規処置
JP2006525995A (ja) * 2003-04-02 2006-11-16 セル ジェネシス インコーポレイテッド サイトカイン発現細胞ワクチンの組み合わせ
JP2011252006A (ja) * 2003-04-02 2011-12-15 Cell Genesys Inc サイトカイン発現細胞ワクチンの組み合わせ
JP2014169299A (ja) * 2003-04-02 2014-09-18 Aduro Gvax Inc サイトカイン発現細胞ワクチンの組み合わせ
JP2011511772A (ja) * 2008-01-31 2011-04-14 アジルクス リミテッド ワクチン組成物
JP2017165734A (ja) * 2011-01-04 2017-09-21 シラジェン バイオセラピューティクス インコーポレイテッド 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
US10434169B2 (en) 2011-01-04 2019-10-08 Sillajen, Inc Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

Also Published As

Publication number Publication date
AU767842B2 (en) 2003-11-27
CA2349217C (en) 2012-07-31
US20070212739A1 (en) 2007-09-13
US7226606B2 (en) 2007-06-05
CA2349217A1 (en) 2000-05-11
US20060078544A1 (en) 2006-04-13
KR20010080384A (ko) 2001-08-22
WO2000026676A1 (en) 2000-05-11
EP1125133A1 (en) 2001-08-22
US7645587B2 (en) 2010-01-12
AU1340900A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
US7645587B2 (en) Cancer-associated antigens and methods of their identification and use
JP4404381B2 (ja) Ｐｓｃａ：前立腺幹細胞抗原
US9404925B2 (en) Cancer antigen and use thereof
JP2006304807A (ja) Ｃ−ｅｒｂＢ−２外部ドメイン：ＧＰ７５
JP2010239970A (ja) 乳癌の処置および診断のための組成物ならびにそれらの使用方法
US7217421B1 (en) Cancer-associated antigens and methods of their identification and use
US20060127408A1 (en) Cancer immunotherapy
JP2004147649A (ja) 頭頚部癌の抗原
Palomba et al. CD8+ T-cell–dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma
JP2008163029A (ja) ＰＡＰ２ａに対する抗体ならびにその診断的および治療的使用
JP2002525098A5 (enExample)
JP2002540789A5 (enExample)
US7897355B2 (en) Gene expressed in prostate cancer and methods of use
US20090304702A1 (en) Gene expressed in prostate cancer and methods of use
CN101437537B (zh) 癌症疫苗
JP2004511758A (ja) 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法
Slovin Prostate-specific membrane antigen vaccines: naked DNA and protein approaches
US20050053988A1 (en) Gene expressed in breast cancer and methods of use
WO2001058947A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy
WO2002036623A2 (en) Ghep, a gene highly expressed in normal and neoplastic prostate, and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100722